Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 905

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Natural history of multiple sclerosis: a unifying concept

Confavreux, Christian, Vukusic, Sandra·2006·Brain

Abstract

Multiple sclerosis can follow very different patterns of evolution and variable rates of disability accumulation. This raises the issue whether it represents one or several distinct diseases. We assessed demographic and clinical characteristics in 1844 patients with multiple sclerosis that we categorized according to the classification of Lublin and Reingold (1996) into 1066 (58%) relapsing-remitting, 496 (27%) secondary progressive, 109 (6%) progressive relapsing and 173 (9%) primary progressive cases of multiple sclerosis. Relapsing-remitting and secondary progressive cases shared similar age at disease onset (median = 28.7 versus 29.5 years; P = 0.21), initial symptoms of the relapsing-remitting phase, degree of recovery from the first neurological episode, and time from the first to the second episode. By contrast, disease duration was twice as long in secondary progressive than in relapsing-remitting cases (mean +/- SD = 17.6 +/- 9.6 versus 8.7 +/- 8.6 years; P < 0.001). Progressive relapsing and primary progressive cases were essentially similar in their clinical characteristics. In patients experiencing a progressive course, median age at onset of progressive phase was similar in secondary progressive cases and in cases who were progressive from onset (39.1 versus 40.1 years; P = 0.47). The proportion of cases with superimposed relapses during progression was approximately 40% in both categories. Finally, the 1562 patients with an exacerbating-remitting initial course and the 282 patients with a progressive initial course of the disease were essentially similar with respect to the time course of disability accumulation from assignment to a given disability score, and the age at assignment of disability landmarks. These observational data suggest that the clinical phenotype and course of multiple sclerosis are age dependent. Relapsing-remitting disease can be regarded as multiple sclerosis in which insufficient time has elapsed for the conversion to secondary progression; secondary progressive forms as relapsing-remitting multiple sclerosis that has 'grown older'; and progressive from onset cases as multiple sclerosis 'amputated' from the usual preceding relapsing-remitting phase. Times to reach disability milestones, and ages at which these landmarks are reached, follow a predefined schedule not obviously influenced by relapses, whenever they may occur, or by the initial course of the disease, whatever its phenotype. This leads to a unifying concept of the disease in which primary and secondary progression might be regarded as essentially similar. From the clinical and statistical positions, multiple sclerosis might be considered as one disease with different clinical phenotypes rather than an entity encompassing several distinct diseases-the position of complexity rather than true heterogeneity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awl007

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 50

  1. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci2000; 21 (Suppl): 831–8. · DOI
  2. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset. Clinical characteristics and progression of disability. Arch Neurol1999; 56: 1138–42. · doi:10.1001/archneur.56.9.1138
  3. Arnold DL. Magnetic resonance spectroscopy: imaging axonal damage in MS. J Neuroimmunol1999; 98: 2–6. · DOI
  4. Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JL, Plant GT, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology2000; 54: 1689–91. · DOI · Paper page
  5. Broman T, Andersen O, Bergmann L. Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand1981; 63: 6–33. · DOI
  6. Ciccarelli O, Werring DJ, Wheeler-Kingshott CAM, Barker GJ, Parker GJ, Thompson AJ, et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology2001; 56: 926–33. · DOI · Paper page
  7. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain1980; 103: 281–300. · DOI · Paper page
  8. Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European Database for Multiple Sclerosis. J Neurol Neurosurg Psychiatry1992; 55: 671–6. · DOI · Paper page
  9. Confavreux C, Vukusic S. Natural History of Multiple Sclerosis: implications for counseling and therapy. Curr Opin Neurol2002; 15: 257–66. · DOI
  10. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain2006; 129: 595–605. First published January 16, 2006, doi:10.1093/brain/awh714. · DOI · Paper page
  11. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain2003; 126: 770–82. · DOI · Paper page
  12. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–8. · DOI · Paper page
  13. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain1999; 122:625–39. · DOI · Paper page
  14. Eriksson M, Andersen O, Runmarker B. Long-term follow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler2003; 9: 260–74. · DOI · Paper page
  15. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol2000; 47: 391–5. · doi:10.1002/1531-8249(200003)47:3<391::aid-ana20>3.0.co;2-j
  16. Filippi M, Campi A, Martinelli V, Pereira C, Scotti G, Comi G. Transitional progressive multiple sclerosis: MRI and MTI findings. Acta Neurol Scand1995; 92: 178–82. · doi:10.1111/j.1600-0404.1995.tb01036.x
  17. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain2003; 126: 433–7. · DOI · Paper page
  18. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet2004; 364: 1489–96. · DOI · Paper page
  19. Fox NC, Jenkins R, Lary SM, Stevenson VL, Losseff NA, Crum WR, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology2000; 54: 807–12. · DOI · Paper page
  20. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain1998; 121: 103–13. · DOI · Paper page
  21. Gayou A, Brochet B, Dousset V. Transitional progressive multiple sclerosis: a clinical and imaging study. J Neurol Neurosurg Psychiatry1997; 63: 396–8. · DOI
  22. Ingle GT, Stevenson VL, Miller DH and Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain2003; 126: 2528–36. · DOI
  23. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain1999; 122: 1941–9. · DOI
  24. Kurtzke JF. On the evaluation of disability in multiple sclerosis. Neurology1961; 11: 686–94. · DOI · Paper page
  25. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain1996; 119: 2009–19. · DOI · Paper page
  26. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain1996; 119: 701–8. · DOI · Paper page
  27. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology1996; 46: 907–11. · DOI · Paper page
  28. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol2000; 47: 707–17. · DOI
  29. McAlpine D, Compston ND. Some aspects of the natural history of disseminated sclerosis: incidence, course and prognosis; factors affecting onset and course. Q J Med1952; 21: 135–67.
  30. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis:a distinct syndrome? Mult scler1996; 2: 137–41. · DOI
  31. McDonnel GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry1998; 64: 451–4. · DOI
  32. Minderhoud JM, Van der Hoeven JH, Prange AJA. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand1988; 78: 10–5. · DOI
  33. Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Multiple Sclerosis2001; 7: 59–65. · DOI
  34. Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand1982; 65: 248–66. · DOI
  35. Poser S. Multiple sclerosis. An analysis of 812 cases by means of electronic data processing. Berlin: Springer-Verlag; 1978.
  36. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227–31. · DOI · Paper page
  37. Robertson NP, Clayton D, Fraser M, Deans J, Compston DA. Clinical concordance in sibling pairs with multiple sclerosis. Neurology1996; 47: 347–52. · DOI
  38. Rudick RA, Fischer E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology1999; 53: 1698–704. · DOI · Paper page
  39. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain1993; 116: 117–34. · DOI · Paper page
  40. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Problems of experimental trials of therapy in MS: report by the panel on the evaluation of experimental trials of therapy in MS. Ann N Y Acad Sci1965; 122: 552–68. · DOI · Paper page
  41. Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, et al. Primary and transitional progressive MS. A clinical and MRI cross-sectional study. Neurology1999; 52: 839–45. · DOI · Paper page
  42. Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, et al. One year follow-up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry2000; 68: 713–8. · DOI
  43. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol1991; 29: 53–62. · DOI · Paper page
  44. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et al. Primary progressive multiple sclerosis. Brain1997; 120: 1085–96. · DOI · Paper page
  45. Tortorella C, Viti B, Bozzali M, Sormani MP, Rizzo G, Gilardi MF, et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology2000; 54: 186–93. · DOI · Paper page
  46. Traboulsee A, Dehmeshki J, Brex PA, Dalton CM, Chard D, Barker GJ, et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology2002; 59: 126–8. · DOI
  47. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci2003; 206: 135–7. · DOI
  48. Weinshenker BG. Progressive forms of MS: classification streamlined or consensus overtuned? Lancet2000; 355: 162–3. · DOI
  49. Weinshenker BG, Bulman D, Carriere W, Baskerville J, Ebers GC. A comparison of sporadic and familial multiple sclerosis. Neurology1990; 40: 1354–8. · DOI
  50. Youl BD, Turano G, Miller DH, Towell AD, MacManus DG, Moore SG, et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain1991; 114: 2437–50. · DOI · Paper page

Cited by

See all 905

Metadata

Authors
Confavreux, C., & Vukusic, S.
Venue
Brain
Published
2006-01-16
Volume
129
Issue
3
Pages
606-616
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2148563799
Cited by
905
References
2
FWCI
21.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural history of multiple sclerosis: a unifying concept. https://app.cochat.ai/papers/10.1093/brain/awl007
The paper
Confavreux, C., & Vukusic, S. (2006). Natural history of multiple sclerosis: a unifying concept. Brain. https://doi.org/10.1093/brain/awl007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.